MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to present at two upcoming investor conferences: Chief Executive Officer Alistair Macdonald is
Highlights Third quarter revenue of $1,348.2 million increased 22.7% year-over-year. Clinical Solutions net new business awards of $1,353.8 million for the third quarter, representing year-over-year growth of 35.0% and a book-to-bill ratio of 1.30x, and $5,322.2 million for the trailing twelve
MORRISVILLE, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial results on Wednesday, November 3rd, 2021, prior to its earnings call at 8:00 a.m. ET.
Acquisition Delivers AI and Data Engineering Expertise, Enterprise Analytics and Technology-Enabled Solutions to Accelerate Customer Performance MORRISVILLE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization,
Partnership Creates a More Patient-centric Travel Experience, Drives Adherence and Advances Diversity and Inclusion in Clinical Research MORRISVILLE, N.C. and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions
MORRISVILLE, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the 2021 Baird
Highlights Second quarter revenue of $1,282.6 million, increased 6.1% sequentially and 26.6% year-over-year. Clinical Solutions net new business awards of $1,436.2 million for the second quarter, representing year-over-year growth of 21.2% and a book-to-bill ratio of 1.45x, and $4,971.5 million for
Partnership will enable biopharma companies to accelerate clinical development, market access, and the uptake of new therapies MORRISVILLE, N.C. and NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH) and Aetion ® announced a partnership to provide regulatory-grade data and
Newly Created Role Demonstrates Company’s Commitment to Growth and Innovation as Industry Leader in Biopharmaceutical Product Development MORRISVILLE, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today
MORRISVILLE, N.C., July 12, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to its earnings call at 8:00 a.m. ET.
Newly Established Site Advocacy Group will Deliver Deeper, More Meaningful Site-Based Insights to Drive Adoption of Decentralized Clinical Trials Methodologies & Technologies MORRISVILLE, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated
MORRISVILLE, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of David S. Wilkes, M.D., to the Company’s Board of Directors. “We are thrilled to welcome Dr.
Consortium Advances Behavioral Insights and Diverse Patient Perspectives Across Product Development Lifecycle MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today launched its Patient Voice
MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H.
MORRISVILLE, N.C., May 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences: Chief Executive Officer Alistair Macdonald is scheduled to
Healthcare Businesswomen’s Association Shines a Light on Lynn Hamilton and Katya Magonova MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Lynn Hamilton, Senior Director,
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of
MORRISVILLE, N.C. , May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H.
Enterprise Partnership Enables Innovative Common Data Foundation Across Clinical, Real-World and Commercial Data by Combining Komodo Health’s Prism and Sentinel Solutions MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical
MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- The Illingworth Research Group, a Syneos Health ® company, has been recognized with a 2021 Queen’s Award for Enterprise for International Trade. Illingworth Research Group™ is a leading global provider of clinical research home health services.
Highlights Revenue of $1,208.7 million for the three months ended March 31, 2021, representing a sequential increase of 6.0% compared to the three months ended December 31, 2020, and a year-over-year increase of 3.9% compared to the three months ended March 31, 2020.
New Partnership Leverages Medable’s Patient-Centered Cloud Platform, Accelerating Seamless Real-World Data Capture and Fit-for-Purpose Decentralized Solutions MORRISVILLE, N.C. and PALO ALTO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated
MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET.
Science 37’s Technology-First Operating System Further Powers Syneos Health’s Decentralized Solutions MORRISVILLE, N.C. and LOS ANGELES, March 29, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Science 37, the
Senior Leaders Bring Decades of Creative, Brand and Strategy Experience MORRISVILLE, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- Syneos Health Communications – the portfolio of Syneos Health ® agencies designed to deliver insights-driven integrated communications spanning advertising, public
MORRISVILLE, N.C. , March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today
MORRISVILLE, N.C. , March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today
Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review MORRISVILLE, N.C. and SALT LAKE CITY , Feb. 24, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Protocol First, Inc.
Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy MORRISVILLE, N.C. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Syneos Health Communications – the portfolio of Syneos Health ® agencies designed to deliver insights-driven integrated communications spanning advertising,
Highlights GAAP revenue of $1,140.0 million for the three months ended December 31, 2020 , representing a sequential increase of 3.7% compared to the three months ended September 30, 2020 . Net new business awards of $1,764.1 million and $5,863.1 million for the three and twelve months ended
Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers MORRISVILLE, N.C. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, is pulsing a
MORRISVILLE, N.C. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 financial results on Thursday, February 18, 2021 , prior to its earnings call at 8:00 a.m. ET .
MORRISVILLE, N.C. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer
